CD47 and neoplasm: Notably, a recent study demonstrated that the combination of CD47/SIRPα inhibition with activation of CD40 signaling using a SIRPα-Fc-CD40L fusion protein also enhances type I interferon responses in macrophages, increasing effector T cell activity, further blocking tumor growth [75].